Abstract:Cancer is a leading cause of death worldwide. Several targeted anticancer drugs entered clinical practice and improved survival of cancer patients with selected tumor types, but therapy resistance and metastatic disease remains a challenge. A major class of targeted anticancer drugs are therapeutic antibodies, but their use is limited to extracellular targets. Hence, alternative binding scaffolds have been investigated for intracellular use and better tumor tissue penetration. Among those, monobodies are small synthetic protein binders that were engineered to bind with high affinity and selectivity to central intracellular oncoproteins and inhibit their signaling. Despite their use as basic research tools, the potential of monobodies as protein therapeutics remains to be explored. In particular, the pharmacological properties of monobodies, including plasma stability, toxicity and pharmacokinetics have not been investigated. Here, we show that monobodies have high plasma stability, are well-tolerated in mice, but have a short half-life in vivo due to rapid renal clearance. Therefore, we engineered monobody fusions with an albumin-binding domain (ABD), which showed enhanced pharmacological properties without affecting their target binding: We found that ABD-monobody fusions display increased stability in mouse plasma. Most importantly, ABD-monobodies have a dramatically prolonged in vivo half-life and are not rapidly excreted by renal clearance, remaining in the blood significantly longer, while not accumulating in specific internal organs. Our results demonstrate the promise and versatility of monobodies to be developed into future therapeutics for cancer treatment. We anticipate that monobodies may be able to extend the spectrum of intracellular targets, resulting in a significant benefit to patient outcome.

Recent advances of affibody molecules in biomedical applications

Radionuclide Molecular Imaging Using Affibody Molecules

Recent Advances on Affibody- and DARPin-Conjugated Nanomaterials in Cancer Therapy

Bacterial Cell Display for Selection of Affibody Molecules

Affibody-derived drug conjugates: Potent cytotoxic molecules for treatment of HER2 over-expressing tumors

Recombinant and Synthetic Affibodies Function Comparably for Modulating Protein Release

Recent Progress in the Molecular Imaging of Therapeutic Monoclonal Antibodies

Influence of molecular design on biodistribution and targeting properties of an Affibody-fused HER2-recognising anticancer toxin

Nanobody: a promising toolkit for molecular imaging and disease therapy

Photocrosslinkable, Low-Affinity Affibodies Show Improved Transport and Retention in 3D Tumor Spheroids

Fc Engineering for Developing Therapeutic Bispecific Antibodies and Novel Scaffolds

Antibody Conjugates-Recent Advances and Future Innovations

IgG Fc Affinity Ligands and Their Applications in Antibody-Involved Drug Delivery: A Brief Review

Self-Assembled Nanomicelles of Affibody-Drug Conjugate with Excellent Therapeutic Property to Cure Ovary and Breast Cancers

Emerging affinity ligands and support materials for the enrichment of monoclonal antibodies

Affimer reagents enable targeted delivery of therapeutic agents and RNA via virus-like particles

Improving the pharmacokinetics, biodistribution and plasma stability of monobodies

Engineered Fc Based Antibody Domains and Fragments As Novel Scaffolds.

Selection and characterization of a novel affibody peptide and its application in a two-site ELISA for the detection of cancer biomarker alpha-fetoprotein

Biological Application of Sulfobetaine Methacrylate Polymers